EZH2 inhibition promotes methyl jasmonate‑induced apoptosis of human colorectal cancer through the Wnt/β‑catenin pathway

Abstract

Abstract. Methyl jasmonate potentially induces the differentiation of human myeloid leukemia cells and inhibits their proliferation; it may induce the differentiation and apoptosis of human lymphocytic leukemia cells, but does not exert a damaging effect on normal lymphocytes. In the present study, the anticancer effect of methyl jasmonate on human colorectal cancer cells was investigated. Cell viability and apoptosis was assessed using a Cell Counting kit-8 assay and flow cytometry, respectively. Methyl jasmonate suppressed cell viability and induced apoptosis in human colorectal cancer cells. Additionally, methyl jasmonate increased the activation of caspase-3, inhibited the expression levels of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) and the Wnt/β-catenin pathway in human colorectal cancer. Downregulation of EZH2 expression enhanced the anticancer effect of methyl jasmonate on human colorectal cancer cells through suppression of the Wnt/β-catenin pathway. Thus, EZH2 downregulation promotes the anticancer effect of methyl jasmonate by inducing apoptosis in human colorectal cancer cells through the Wnt/β-catenin pathway.

Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases

“…The abnormal expression or activation of EZH2 is related to the pathogenesis of AKI Zhou et al, 2018b ). Initially, it was found that EZH2 is involved in many cellular responses, such as apoptosis and inflammation ( Wang Y. et al, 2018 ; Bamidele et al, 2019 ). The expression of EZH2 and H3K27me3 is up-regulated in ischemia-reperfusion and folic acid-induced AKI models ( Zhou et al, 2018b ).…”

Enhancer of zeste homolog 2 modulates oxidative stress‐mediated pyroptosis in vitro and in a mouse kidney ischemia‐reperfusion injury model

“…In the Sham + DZNeP (Selleck, S7120) group, mice were administrated with DZNeP (0.5, 1.0, and 2.5 mg/kg) by intraperitoneal injection for 5 consecutive days before sham operation, once a day. In I/R group, the left renal vessels were blocked using a clamp for 30 min followed by various reperfusion time (6,12,24 h) without any treatments. In I/R + DZNeP group, mice were administrated with DZNeP (0.5, 1.0, and 2.5 mg/kg) by intraperitoneal injection for 5 consecutive days before I/R model established.…”

“…6 Enhancer of zeste homolog 2 (EZH2), a type of histone methyltransferases, is well known as the main catalytic part of polycomb repressive complex 2 (PRC2) and plays a vital role in triggering trimethylation of histone H3 at lysine27, which has been reported to be involved in the progression of a variety of kidney disease models, including renal I/R injury. 11,12 However, the underlying mechanisms and roles of EZH2 in renal I/R injury have not been totally elucidated. 10 Simultaneously, numerous evidences demonstrated that EZH2 was linked to a variety of cellular responses, such as apoptosis and inflammation.…”

Tumor Decelerating and Chemo-Potentiating Action of Methyl Jasmonate on a T Cell Lymphoma In Vivo: Role of Altered Regulation of Metabolism, Cell Survival, Drug Resistance, and Intratumoral Blood Flow

“…The broad-spectrum anticancer action of MJ has been vividly demonstrated against neoplastic cells of diverse origins (1,2). The cytotoxic activity of MJ against neoplastic cells has been shown to implicate a wide variety of molecular mechanisms but majorly through the induction of mitochondrial-mediated apoptotic cell death by involving altered functions of mitochondria (3,4) and causing detachment of hexokinase from VADC (5). However, the bulk of data associated with MJ's antineoplastic action is mainly from in vitro studies performed against a wide variety of neoplastic cell lines (1,2,6,7).…”